within Pharmacolibrary.Drugs.ATC.J;

model J05AP01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.45,
    Cl             = 0.5016666666666667,
    adminDuration  = 600,
    adminMass      = 0.6,
    adminCount     = 1,
    Vd             = 0.649,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.007166666666666667,
    Tlag           = 22.2
  );

  annotation(Documentation(
    info ="<html><body><p>Ribavirin is a synthetic nucleoside analog with broad-spectrum antiviral activity. It is primarily used for the treatment of hepatitis C in combination with other drugs and for severe respiratory syncytial virus (RSV) infections in certain populations. Ribavirin is approved for use in combination therapy for hepatitis C virus (HCV) infection and is also used off-label for other viral infections.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult males after single oral dose.</p><h4>References</h4><ol><li><p>K Gupta, S, et al., &amp; Glue, P (2014). Exploring the influence of renal dysfunction on the pharmacokinetics of ribavirin after oral and intravenous dosing. <i>Drug discoveries &amp; therapeutics</i> 8(2) 89–95. DOI:<a href=&quot;https://doi.org/10.5582/ddt.8.89&quot;>10.5582/ddt.8.89</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24815584/&quot;>https://pubmed.ncbi.nlm.nih.gov/24815584</a></p></li><li><p>Glue, P (1999). The clinical pharmacology of ribavirin. <i>Seminars in liver disease</i> 19 Suppl 1 17–24. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10349689/&quot;>https://pubmed.ncbi.nlm.nih.gov/10349689</a></p></li><li><p>Vispo, E, et al., &amp; Soriano, V (2013). Pharmacokinetics of new oral hepatitis C antiviral drugs. <i>Expert opinion on drug metabolism &amp; toxicology</i> 9(1) 5–16. DOI:<a href=&quot;https://doi.org/10.1517/17425255.2013.729577&quot;>10.1517/17425255.2013.729577</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23094639/&quot;>https://pubmed.ncbi.nlm.nih.gov/23094639</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J05AP01;
